Trial · NCT06788938
Tarlatamab in Advanced Delta-like 3 (DLL3)-Expressing Tumors Including Neuroendocrine Neoplasms
NCT06788938, Phase 2, Active not recruiting, Jonsson Comprehensive Cancer Center
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Tarlatamab in Advanced Delta-like 3 (DLL3)-Expressing Tumors Including Neuroendocrine Neoplasms. Trials, record NCT06788938. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06788938
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Tarlatamab in Advanced Delta-like 3 (DLL3)-Expressing Tumors Including Neuroendocrine Neoplasms
- NCT number
- NCT06788938
- Status
- Active not recruiting
- Phases
- Phase 2
- Enrollment
- 29 participants, estimated
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Conditions
- DLL3-expressing Tumors, Advanced Tumors
- Interventions
- Tarlatamab treatment
- First posted
- 2025-01-23
- Last updated
- 2026-09-01
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | 1. Primary efficacy endpoint is overall response rate (ORR) as defined as complete response (CR) or partial response (PR) by RECIST 1.1 criteria. This is evaluated in the response evaluable set of patients. | 18 months | |
| Secondary | Duration of response (DOR) | 18 months | Duration of response, defined as time from the first documentation of OR until the first documentation of disease progression or death due to any cause, whichever occurs first. Only participants who have achieved OR will be evaluated for DOR |
| Secondary | Progression free survival (PFS) | 18 months | Progression free survival (PFS) is defined as time from randomization until disease progression based on RECIST 1.1, or death from any cause, whichever occurs first. |
| Secondary | Overall Survival (OS) | 18 months | OS is defined as time from randomization until death from any cause. |
| Secondary | Safety and tolerability | 18 months | Safety and tolerability of tarlatamab as measured by adverse events defined by Common Terminology Criteria for Adverse Events V5.0 (CTCAE 5.0). CRS and ICANS will be graded per ASTCT Consensus Grading. |
| Other | Biomarker analysis | 18 months | Assessment of potential biomarkers using tissue and based analyses |
| Other | Evaluate radiologic correlates | 18 months | Evaluate radiologic correlates such as DLL3 PET tracer uptake at sites where this is available. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06788938
GET https://conductscience.org/api/trials/v1/NCT06788938/registered